AbbVie Inc. P/S ratio

P/S ratio of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including P/S ratio growth rates and interactive chart. A valuation metric that measures the share price of a stock compared to its sales per share. It is used by investors mainly because it’s less volatile than P/E and less subject to accounting manipulation. A low P/S ratio compare to historical average or other companies in the same industry might indicate undervaluation.


Highlights and Quick Summary

Current P/S ratio of AbbVie Inc. is 3.9 (as of December 30, 2020)
  • P/S ratio for the quarter ending December 30, 2020 was 3.9 (a 2.31% increase compared to previous quarter)
  • Year-over-year quarterly P/S ratio increased by 17.7%
  • Annual P/S ratio for 2020 was 3.9 (a -1.07% decrease from previous year)
  • Annual P/S ratio for 2019 was 3.94 (a -9.12% decrease from previous year)
  • Annual P/S ratio for 2018 was 4.34 (a -22.08% decrease from previous year)
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical P/S ratio of AbbVie Inc.

Most recent P/S ratioof ABBV including historical data for past 10 years.

Interactive Chart of P/S ratio of AbbVie Inc.

AbbVie Inc. P/S ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 3.9 3.81 4.46 3.31 3.9
2019 3.94 3.41 3.33 3.66 3.94
2018 4.34 4.46 4.72 4.91 4.34
2017 5.57 5.29 4.33 3.97 5.57
2016 3.95 4.08 4.06 3.88 3.95
2015 4.21 4.1 5.19 4.57 4.21
2014 5.23 4.7 4.67 4.31 5.23
2013 4.47 3.77 3.53 3.52 4.47
2012 3.01 3.01 3.01 3.01 3.01
2011 3.01 3.01 3.01 3.01 3.01
2010 3.01

Business Profile of AbbVie Inc.

Sector: Healthcare
Industry: Drug Manufacturers—General
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.